S-Methyl cysteine sulfoxide: its effects on cardiometabolic outcomes in high-fat fed C57BL/6 mice and relevance to human health

Abstract

S-Methyl cysteine sulfoxide (SMCSO) is an organosulfur compound with demonstrated hypocholesterolemic, anti-diabetic, and antioxidant benefits in rodents. However, the doses used have limited translatability for humans. We explored whether SMCSO could blunt development of diet-induced metabolic syndrome features in mice using doses that are potentially more translatable and achievable in humans. Male mice (C57BL/6; n = 54) were randomly assigned into one of five groups: [1] normal-diet; [2] high-fat-diet; or high-fat-diet with [3] 60 mg kg−1, [4] 170 mg kg−1, or [5] 350 mg per kg per body weight (BW) of SMCSO, respectively. Doses were administered five days per week for 12 weeks via gavage. Repeated measure analysis of variance (ANOVA) was used to determine changes over time. One-way ANOVA with Dunnett's post hoc analysis determined differences between groups for all parametric data, with Kruskal–Wallis with Dunn's test used for non-parametric data. The high-fat fed group (group 2) was the comparator for all analyses with statistical significance set at p < 0.05. High-fat fed mice experienced weight gain, impaired glucose tolerance, elevated total cholesterol, high-density lipoprotein-cholesterol (HDL-C), and measured low-density lipoprotein-cholesterol (mLDL-C), compared to normal-diet fed mice (all p < 0.05). Adding 170 mg kg−1 and 350 mg per kg BW per day of SMCSO reduced diet-induced elevations in HDL-C (−11 to −12%), whilst 350 mg per kg per BW day lowered triglycerides (−16%), compared to high-fat fed mice (all p ≤ 0.05). Other cardiometabolic parameters were not significantly altered. SMCSO did not improve glucose tolerance, mLDL-C, or blunt weight gain in high-fat fed mice. The higher SMCSO doses (170 and 350 mg per kg BW per day) lowered diet-induced elevations in HDL-C, although the mechanism is unclear. Whether this finding has relevance to human health remains unknown.

Graphical abstract: S-Methyl cysteine sulfoxide: its effects on cardiometabolic outcomes in high-fat fed C57BL/6 mice and relevance to human health

Supplementary files

Article information

Article type
Paper
Submitted
07 Nov 2025
Accepted
22 Mar 2026
First published
27 Apr 2026
This article is Open Access
Creative Commons BY license

Food Funct., 2026, Advance Article

S-Methyl cysteine sulfoxide: its effects on cardiometabolic outcomes in high-fat fed C57BL/6 mice and relevance to human health

C. R. Hill, L. Balmer, H. Abbiss, J. M. Hodgson, J. R. Lewis, A. Shafaei and L. C. Blekkenhorst, Food Funct., 2026, Advance Article , DOI: 10.1039/D5FO04816H

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements